fluorouracil has been researched along with Microsatellite Instability in 138 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Microsatellite Instability: The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the present study was to evaluate the gene expression of the DNA mismatch repair gene MSH2 as a predictive marker in advanced colorectal cancer (CRC) treated with first-line capecitabine." | 9.12 | Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Jensen, LH, 2007) |
| "Adjuvant chemotherapy with 5-fluorouracil (5-FU) does not improve survival of patients suffering from a form of colorectal cancer (CRC) characterized by high level of microsatellite instability (MSI-H)." | 8.02 | Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition. ( Behrouj, H; Dastghaib, S; Ghavami, S; Hudecki, J; Khazayel, S; Likus, W; Mokarram, P; Rezaie, S; Siri, M; Zamani, M; Łos, MJ, 2021) |
| "The impact of microsatellite instability (MSI) on survival in stage III colon cancer treated with adjuvant 5-fluorouracil-oxaliplatin combination (FOLFOX) chemotherapy is not clear." | 7.85 | Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX). ( Hong, YS; Kim, CW; Kim, HJ; Kim, JC; Kim, JE; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lim, SB; Park, IJ; Yoon, YS; Yu, CS, 2017) |
| "Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy." | 7.80 | Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. ( Arzouk, H; Bengrine-Lefèvre, L; Biard, DS; Bouvier, AM; Buhard, O; Chapusot, C; Collura, A; Coquelle, A; De Thonel, A; Delarue, P; Dorard, C; Duval, A; Fléjou, JF; Garrido, C; Gaub, MP; Guilloux, A; Iacopetta, B; Lacoste, C; Lagrange, A; Lefèvre, JH; Lepage, C; Loh, M; Marcion, G; Marisa, L; Mews, A; Milano, G; Parc, Y; Platell, C; Saget, A; Seigneuric, R; Selves, J; Senet, P; Soong, R; Svrcek, M; Taieb, A; Tournigand, C; Wanherdrick, K; Zeps, N, 2014) |
| "Mucinous colorectal cancer (CRC) exhibits distinct clinical and pathological features, including poorer response to fluorouracil (FU) compared with non-mucinous tumours." | 7.79 | Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. ( Ardizzoni, A; Azzoni, C; Bottarelli, L; Campanini, N; Cascinu, S; Cunningham, D; Mandolesi, A; Negri, FV; Scartozzi, M; Silini, EM; Tinelli, C; Wotherspoon, A, 2013) |
| " Deficient mismatch repair, or microsatellite instability, is a potent marker for the ineffectiveness of 5-fluorouracil (5-FU) in colorectal cancer (CRC)." | 7.78 | FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer. ( Fujinaka, Y; Iimori, M; Kakeji, Y; Kitao, H; Maehara, Y; Morita, M; Nakanishi, R; Tokunaga, E; Yamashita, N, 2012) |
| "The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX)." | 7.76 | Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. ( Cuilliere-Dartigues, P; de Gramont, A; Dumont, S; Duval, A; Fléjou, JF; Gayet, B; Guilloux, A; Louvet, C; Parc, Y; Praz, F; Tiret, E; Validire, P; Zaanan, A, 2010) |
| "The aim of this study is to evaluate if mismatch repair (MMR) defective colorectal cancer has a different response to adjuvant 5-fluorouracil (5-FU) chemotherapy in a cohort of patients prospectively followed during 5 years." | 7.75 | The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Pons, E; Reñé, JM; Sempere, L; Xicola, RM; Zapater, P, 2009) |
| "DNA microsatellite instability was also assessed using a panel of mono- and dinucleotide markers." | 6.74 | Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. ( Bertagnolli, MM; Compton, CC; Damas, B; Goldberg, RM; Hahn, HP; Hall, M; Jewell, SD; Mayer, RJ; Niedzwiecki, D; Redston, M; Saltz, LB; Warren, RS, 2009) |
| "Some gastric cancer studies have reported that MSI has no apparent impact on prognosis after patients receive 5-FU-based adjuvant chemotherapy." | 6.61 | Predicting the Efficacy of 5-Fluorouracil-Based Adjuvant Chemotherapy in Gastric Cancer by Microsatellite Instability: A Meta-Analysis. ( Ahmad, R; Ma, Z; Ren, D; Shen, G; Wang, Z; Yuan, X; Zhao, F; Zhao, J; Zheng, F, 2019) |
| "Xenografted patient-derived colon cancer tissues with MSI also show variable patterns of HDAC2 expression in mice." | 5.91 | The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. ( Brachetti, C; Brenner, W; Kiweler, N; Krämer, OH; Linnebacher, M; Matschos, S; Mullins, C; Nguyen, A; Piée-Staffa, A; Roos, WP; Schneider, G; Schwarz, H, 2023) |
| "In this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR colorectal cancer who had not previously received treatment were randomly assigned, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks or chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab) every 2 weeks." | 5.34 | Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. ( André, T; Benavides, M; Bendell, J; de la Fouchardiere, C; Diaz, LA; Elez, E; Farooqui, MZH; Garcia-Carbonero, R; Gibbs, P; Jensen, BV; Jensen, LH; Kim, TW; Le, DT; Marinello, P; Punt, C; Rivera, F; Shiu, KK; Smith, D; Van Cutsem, E; Yang, P; Yoshino, T, 2020) |
| "Microsatellite instability is a recognised pathway of colorectal carcinogenesis responsible for about 15% of all sporadic colorectal cancers." | 5.33 | 5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. ( Kaufman, A; Ramanathan, P; Robinson, BG; Schnitzler, M; Warusavitarne, J, 2006) |
| "Colorectal cancer (CRC) patients whose tumours have microsatellite instability (MSI) do not benefit from adjuvant 5-fluorouracil." | 5.14 | Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. ( Bennamoun, M; Boisseau, A; Cucherousset, J; Des Guetz, G; Lagorce, C; Lecaille, C; Mariani, P; Morere, JF; Nicolas, P; Sastre, X; Schischmanoff, PO; Uzzan, B, 2010) |
| "The objective of the present study was to evaluate the gene expression of the DNA mismatch repair gene MSH2 as a predictive marker in advanced colorectal cancer (CRC) treated with first-line capecitabine." | 5.12 | Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Jensen, LH, 2007) |
| "Gastric cancer (GC) with microsatellite instability (MSI) is a less aggressive disease and associated with resistance to 5-fluorouracil (5-FU)-based chemotherapy (CMT)." | 4.12 | Gastric cancer with microsatellite instability displays increased thymidylate synthase expression. ( Cardili, L; Dias, AR; Mello, ES; Moraes, RDR; Nahas, SC; Pereira, MA; Ramos, MFKP; Ribeiro, U; Zilberstein, B, 2022) |
| "Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has recently become the gold standard treatment for fit patients with operable gastric (GC) or gastroesophageal (GEJ) adenocarcinoma, getting a 5-year overall survival (OS) of 45%, over 23% with surgery alone." | 4.02 | Results of the observational prospective RealFLOT study. ( Antonuzzo, L; Brugia, M; De Vita, F; Di Donato, S; Fancelli, S; Formica, V; Fornaro, L; Giommoni, E; Giovanardi, F; Iachetta, F; Lavacchi, D; Pecora, I; Pillozzi, S; Pompella, L; Pozzo, C; Prisciandaro, M; Puzzoni, M; Romagnani, A; Satolli, MA; Sisani, M; Spallanzani, A; Stragliotto, S; Strippoli, A; Tirino, G, 2021) |
| "Adjuvant chemotherapy with 5-fluorouracil (5-FU) does not improve survival of patients suffering from a form of colorectal cancer (CRC) characterized by high level of microsatellite instability (MSI-H)." | 4.02 | Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition. ( Behrouj, H; Dastghaib, S; Ghavami, S; Hudecki, J; Khazayel, S; Likus, W; Mokarram, P; Rezaie, S; Siri, M; Zamani, M; Łos, MJ, 2021) |
| "The impact of microsatellite instability (MSI) on survival in stage III colon cancer treated with adjuvant 5-fluorouracil-oxaliplatin combination (FOLFOX) chemotherapy is not clear." | 3.85 | Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX). ( Hong, YS; Kim, CW; Kim, HJ; Kim, JC; Kim, JE; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lim, SB; Park, IJ; Yoon, YS; Yu, CS, 2017) |
| "The two key aspects associated with the microsatellite instability (MSI) as genetic phenomenon in colorectal cancer (CRC) are better survival prognosis, and the varying response to 5-fluorouracil (5-FU)-based chemotherapy." | 3.83 | Microsatellite instability & survival in patients with stage II/III colorectal carcinoma. ( Branimir, Z; Daniela, B; Ivan, D; Jadranka, A; Petar, S; Srdjan, M; Velimir, M; Zoran, K, 2016) |
| "Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy." | 3.80 | Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. ( Arzouk, H; Bengrine-Lefèvre, L; Biard, DS; Bouvier, AM; Buhard, O; Chapusot, C; Collura, A; Coquelle, A; De Thonel, A; Delarue, P; Dorard, C; Duval, A; Fléjou, JF; Garrido, C; Gaub, MP; Guilloux, A; Iacopetta, B; Lacoste, C; Lagrange, A; Lefèvre, JH; Lepage, C; Loh, M; Marcion, G; Marisa, L; Mews, A; Milano, G; Parc, Y; Platell, C; Saget, A; Seigneuric, R; Selves, J; Senet, P; Soong, R; Svrcek, M; Taieb, A; Tournigand, C; Wanherdrick, K; Zeps, N, 2014) |
| "The prognostic impact of CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) on the treatment outcome of colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) is unclear." | 3.79 | Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. ( Bae, JM; Bang, YJ; Cho, NY; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, HJ; Lee, KH; Oh, DY; Park, JG; Park, KJ, 2013) |
| "Mucinous colorectal cancer (CRC) exhibits distinct clinical and pathological features, including poorer response to fluorouracil (FU) compared with non-mucinous tumours." | 3.79 | Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. ( Ardizzoni, A; Azzoni, C; Bottarelli, L; Campanini, N; Cascinu, S; Cunningham, D; Mandolesi, A; Negri, FV; Scartozzi, M; Silini, EM; Tinelli, C; Wotherspoon, A, 2013) |
| "Microsatellite instability (MSI) is a distinct molecular phenotype of colorectal cancer related to prognosis and tumour response to 5-fluorouracil (5-FU)-based chemotherapy." | 3.78 | The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. ( Cheon, JH; Hong, SP; Kim, H; Kim, NK; Kim, TI; Kim, WH; Min, BS, 2012) |
| " Deficient mismatch repair, or microsatellite instability, is a potent marker for the ineffectiveness of 5-fluorouracil (5-FU) in colorectal cancer (CRC)." | 3.78 | FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer. ( Fujinaka, Y; Iimori, M; Kakeji, Y; Kitao, H; Maehara, Y; Morita, M; Nakanishi, R; Tokunaga, E; Yamashita, N, 2012) |
| "The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX)." | 3.76 | Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. ( Cuilliere-Dartigues, P; de Gramont, A; Dumont, S; Duval, A; Fléjou, JF; Gayet, B; Guilloux, A; Louvet, C; Parc, Y; Praz, F; Tiret, E; Validire, P; Zaanan, A, 2010) |
| "Conflicting data exist regarding the relevance of high-frequency microsatellite instability (MSI-H) for predicting the prognosis and benefits of 5-fluorouracil (5-FU)-based chemotherapy." | 3.75 | Chemosensitivity and survival in gastric cancer patients with microsatellite instability. ( Ando, K; Kakeji, Y; Maehara, Y; Masuda, T; Morita, M; Ohgaki, K; Oki, E; Yoshida, R; Zhao, Y, 2009) |
| "The aim of this study is to evaluate if mismatch repair (MMR) defective colorectal cancer has a different response to adjuvant 5-fluorouracil (5-FU) chemotherapy in a cohort of patients prospectively followed during 5 years." | 3.75 | The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Pons, E; Reñé, JM; Sempere, L; Xicola, RM; Zapater, P, 2009) |
| "MSI in five reference loci, MMR enzymes (hMSH2, hMSH6, hMLH1 and hPMS2), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) expression were assessed in paraffin embedded tumor specimens, and associated with outcome in 340 consecutive patients completely resected for colorectal cancer stages II-IV and subsequently receiving adjuvant 5-fluorouracil therapy." | 3.75 | Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. ( Jensen, SA; Kruhøffer, M; Sørensen, JB; Vainer, B, 2009) |
| "Colorectal cancer (CRC) cell lines displaying microsatellite instability (MSI) are resistant to 5-fluorouracil (5-FU) in vitro, which can be overcome by restoring DNA mismatch repair (MMR) competence." | 3.74 | Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases. ( Bendardaf, R; Korkeila, E; Lamlum, H; Pyrhönen, S; Ristamäki, R; Syrjänen, K, 2008) |
| "This study aimed to investigate the effect of the mFOLFOX6 regimen combined with SHR-1210 on immune function and prognosis in patients with microsatellite instability CRC." | 3.11 | Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer. ( Lu, P; Sun, J; Wang, Y; Yao, N, 2022) |
| "AtezoTRIBE is a prospective, open label, phase II, comparative trial in which initially unresectable and previously untreated mCRC patients, irrespective of microsatellite status, are randomized in a 1:2 ratio to receive up to 8 cycles of FOLFOXIRI/bevacizumab alone or in combination with atezolizumab, followed by maintenance with bevacizumab plus 5-fluoruracil/leucovorin with or without atezolizumab according to treatment arm until disease progression." | 2.94 | AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. ( Antoniotti, C; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Brunella, DS; Corallo, S; Cremolini, C; Falcone, A; Grassi, E; Lonardi, S; Marmorino, F; Morano, F; Moretto, R; Pietrantonio, F; Racca, P; Rossini, D; Salvatore, L; Tamberi, S; Tamburini, E; Tortora, G, 2020) |
| "Patients with resected stage III colon cancer (CC) from seven adjuvant studies with available data for disease recurrence and MMR and BRAFV600E status were analyzed." | 2.90 | Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. ( Alberts, S; André, T; de Gramont, A; Grothey, A; Kerr, R; Lonardi, S; Pederson, L; Shi, Q; Sinicrope, FA; Taieb, J; Van Cutsem, E; Wolmark, N; Yoshino, T; Yothers, G; Zaanan, A, 2019) |
| "Although colon cancer (CC) with microsatellite instability (MSI) has a more favorable prognosis than microsatellite stable (MSS) CC, the impact varies according to clinicopathological parameters." | 2.80 | Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. ( Bosman, FT; Delorenzi, M; Klingbiel, D; Roth, AD; Saridaki, Z; Tejpar, S, 2015) |
| "Patients with MSI-H (n=34) colon cancer presented with a significantly lower risk of relapse after 12 months of follow-up compared with MSS (n=189) colon cancer patients (5 year time to relapse: MSI-H 0." | 2.77 | Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. ( Benner, A; Dippold, W; Formentini, A; Kloor, M; Kornmann, M; Link, KH; Michel, S; Tikidzhieva, A; von Knebel Doeberitz, M, 2012) |
| "DNA microsatellite instability was also assessed using a panel of mono- and dinucleotide markers." | 2.74 | Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. ( Bertagnolli, MM; Compton, CC; Damas, B; Goldberg, RM; Hahn, HP; Hall, M; Jewell, SD; Mayer, RJ; Niedzwiecki, D; Redston, M; Saltz, LB; Warren, RS, 2009) |
| "The MSI phenotype in colon cancer is a good prognostic factor, with an impact probably more pronounced for stage II than stage III tumor." | 2.61 | [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?] ( Taieb, J; Zaanan, A, 2019) |
| "Pancreatic cancer is typically diagnosed in the late stage of the disease, making it the fourth leading cause of cancer-related death in the United States." | 2.61 | Managing the economic impact of advanced pancreatic cancer. ( Soefje, SA, 2019) |
| "Some gastric cancer studies have reported that MSI has no apparent impact on prognosis after patients receive 5-FU-based adjuvant chemotherapy." | 2.61 | Predicting the Efficacy of 5-Fluorouracil-Based Adjuvant Chemotherapy in Gastric Cancer by Microsatellite Instability: A Meta-Analysis. ( Ahmad, R; Ma, Z; Ren, D; Shen, G; Wang, Z; Yuan, X; Zhao, F; Zhao, J; Zheng, F, 2019) |
| "Microsatellite instability is the consequence of a deficient mismatch repair system." | 2.49 | Role of microsatellite instability in the management of colorectal cancers. ( Buecher, B; Cacheux, W; Dieumegard, B; Lièvre, A; Mitry, E; Rouleau, E, 2013) |
| "Many patients with early-stage colon cancer are cured with surgery alone, even if the standard of care remains an uniform approach to adjuvant chemotherapy based primarily on tumour stage." | 2.46 | Adjuvant colon cancer chemotherapy: where we are and where we'll go. ( Cinieri, S; Colucci, G; Fazio, N; Lombardi, L; Maiello, E; Morelli, F; Orlando, L; Santini, D; Silvestris, N; Tonini, G, 2010) |
| "Advances in systemic therapy for colorectal cancer have dramatically improved prognosis." | 2.44 | The role of molecular markers in predicting response to therapy in patients with colorectal cancer. ( Benson, AB; Mulcahy, MF; Shankaran, V; Wisinski, KB, 2008) |
| "Xenografted patient-derived colon cancer tissues with MSI also show variable patterns of HDAC2 expression in mice." | 1.91 | The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. ( Brachetti, C; Brenner, W; Kiweler, N; Krämer, OH; Linnebacher, M; Matschos, S; Mullins, C; Nguyen, A; Piée-Staffa, A; Roos, WP; Schneider, G; Schwarz, H, 2023) |
| "In stage 3 colon cancer oncologists had an equal decision "to do or not to do" in MSI testing." | 1.72 | The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer. ( Araz, M; Aykan, NF; Baykara, M; Beypinar, I; Demir, H, 2022) |
| "In patients with stage III colon cancer (CC) whose tumors demonstrate microsatellite instability (MSI), the efficacy of adjuvant fluoropyrimidine (FP) with or without oxaliplatin has not been clearly demonstrated and the prognostic value of MSI remains uncertain." | 1.62 | Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. ( Alberts, S; Allegra, C; André, T; Cohen, R; de Gramont, A; Erlichman, C; Fiskum, J; Goldberg, R; Grothey, A; Haller, D; Kerr, R; Lonardi, S; O'Connell, M; Seitz, JF; Shi, Q; Sinicrope, FA; Taieb, J; Wolmark, N; Yoshino, T; Yothers, G; Zaniboni, A, 2021) |
| "Management of advanced intrahepatic cholangiocarcinoma (iCCA) is challenging and overall survival is poor." | 1.51 | Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. ( Gbolahan, O; Hashemi-Sadraei, N; O'Neil, B, 2019) |
| "The predictive role of biomarkers in colon cancer is still being defined." | 1.48 | The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer. ( Chouhan, H; Moore, JW; Sammour, T; Thomas, ML, 2018) |
| "In patients with colorectal cancer (CRC), the BRAF V600E mutation has been reported to be associated with several clinicopathological features and poor survival." | 1.46 | BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. ( Han, HS; Hwang, DY; Hwang, TS; Jang, MH; Kim, S; Kim, WS; Kim, WY; Lim, SD, 2017) |
| "The microsatellite-instable gastric cancer subtype, because of its supposed high antigenic potential, is a promising candidate for immunotherapy." | 1.46 | Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. ( Andrikou, K; Bianconi, M; Bittoni, A; Bracci, R; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Mandolesi, A; Scarpelli, M; Scartozzi, M, 2017) |
| "Its role in tumorigenesis is more controversial and both the presence and the absence of autophagy have been implicated." | 1.42 | Autophagy is upregulated during colorectal carcinogenesis, and in DNA microsatellite stable carcinomas. ( Benincasa, M; Magnani, G; Mancini, S; Mariani, F; Palumbo, C; Pedroni, M; Roncucci, L; Sena, P, 2015) |
| "Recommendations on systemic therapy in colorectal cancer were produced." | 1.42 | Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer. ( , 2015) |
| "Compared with MSI-L/MSS colon cancer, patients with MSI-H colon cancer had no significant difference in 5-year disease-free and OS (72." | 1.39 | Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer. ( Kim, DY; Kim, YB; Oh, SY; Suh, KW, 2013) |
| "MSI status in gastric cancer is not itself a prognostic indicator." | 1.38 | Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. ( An, JY; Cheong, JH; Hyung, WJ; Kim, H; Noh, SH, 2012) |
| "However, its role in colorectal cancer (CRC) pathobiology and clinical relevance remains unknown." | 1.37 | Overexpression of neurone glial-related cell adhesion molecule is an independent predictor of poor prognosis in advanced colorectal cancer. ( Chan, JY; Ong, CW; Salto-Tellez, M, 2011) |
| "Patients with dMMR colon cancers have reduced rates of tumor recurrence, delayed TTR, and improved survival rates, compared with pMMR colon cancers." | 1.37 | DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. ( Allegra, C; Foster, NR; Gallinger, S; Kim, GP; Labianca, R; Marsoni, S; Monges, G; Moore, MJ; Sargent, DJ; Sinicrope, FA; Thibodeau, SN; Yothers, G, 2011) |
| "Microsatellite instability was observed in all VCMsh2 strains and limited to the intestinal mucosa." | 1.36 | An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. ( Bronson, RT; Clark, AB; Edelmann, W; Fan, K; Hou, H; Jelicks, L; Kucherlapati, MH; Kucherlapati, R; Kunkel, TA; Lee, K; Li, H; Lipkin, M; Nguyen, AA; Rosulek, A; Yang, K, 2010) |
| "The human colon cancer cell line LoVo was injected subcutaneously into the necks of five mice to generate a solid tumor." | 1.35 | A simple colostomy implantation model for evaluating colon cancer. ( Ding, Y; Jin, H; Li, VK; Liu, F; Liu, X; Ni, M; Song, Y; Yun, S; Zhou, S, 2009) |
| "Microsatellite instability is a recognised pathway of colorectal carcinogenesis responsible for about 15% of all sporadic colorectal cancers." | 1.33 | 5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. ( Kaufman, A; Ramanathan, P; Robinson, BG; Schnitzler, M; Warusavitarne, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (19.57) | 29.6817 |
| 2010's | 84 (60.87) | 24.3611 |
| 2020's | 27 (19.57) | 2.80 |
| Authors | Studies |
|---|---|
| Siri, M | 1 |
| Behrouj, H | 1 |
| Dastghaib, S | 1 |
| Zamani, M | 1 |
| Likus, W | 1 |
| Rezaie, S | 1 |
| Hudecki, J | 1 |
| Khazayel, S | 1 |
| Łos, MJ | 1 |
| Mokarram, P | 1 |
| Ghavami, S | 1 |
| Giommoni, E | 1 |
| Lavacchi, D | 1 |
| Tirino, G | 1 |
| Fornaro, L | 1 |
| Iachetta, F | 1 |
| Pozzo, C | 1 |
| Satolli, MA | 1 |
| Spallanzani, A | 1 |
| Puzzoni, M | 1 |
| Stragliotto, S | 1 |
| Sisani, M | 1 |
| Formica, V | 1 |
| Giovanardi, F | 1 |
| Strippoli, A | 1 |
| Prisciandaro, M | 1 |
| Di Donato, S | 1 |
| Pompella, L | 1 |
| Pecora, I | 1 |
| Romagnani, A | 1 |
| Fancelli, S | 1 |
| Brugia, M | 1 |
| Pillozzi, S | 1 |
| De Vita, F | 1 |
| Antonuzzo, L | 1 |
| Aggarwal, N | 1 |
| Quaglia, A | 1 |
| McPhail, MJW | 1 |
| Monahan, KJ | 1 |
| Oneda, E | 1 |
| Zaniboni, A | 2 |
| Baxter, NN | 1 |
| Kennedy, EB | 1 |
| Bergsland, E | 1 |
| Berlin, J | 3 |
| George, TJ | 1 |
| Gill, S | 1 |
| Gold, PJ | 1 |
| Hantel, A | 2 |
| Jones, L | 1 |
| Lieu, C | 1 |
| Mahmoud, N | 1 |
| Morris, AM | 1 |
| Ruiz-Garcia, E | 1 |
| You, YN | 1 |
| Meyerhardt, JA | 4 |
| Kiweler, N | 1 |
| Schwarz, H | 1 |
| Nguyen, A | 1 |
| Matschos, S | 1 |
| Mullins, C | 1 |
| Piée-Staffa, A | 1 |
| Brachetti, C | 1 |
| Roos, WP | 1 |
| Schneider, G | 1 |
| Linnebacher, M | 1 |
| Brenner, W | 1 |
| Krämer, OH | 1 |
| Noel, K | 1 |
| Bokhari, A' | 1 |
| Bertrand, R | 1 |
| Renaud, F | 1 |
| Bourgoin, P | 1 |
| Cohen, R | 3 |
| Svrcek, M | 3 |
| Joly, AC | 1 |
| Duval, A | 4 |
| Collura, A | 3 |
| Pereira, MA | 1 |
| Dias, AR | 1 |
| Ramos, MFKP | 1 |
| Cardili, L | 1 |
| Moraes, RDR | 1 |
| Zilberstein, B | 1 |
| Nahas, SC | 1 |
| Mello, ES | 1 |
| Ribeiro, U | 1 |
| Sun, J | 2 |
| Yao, N | 1 |
| Lu, P | 1 |
| Wang, Y | 1 |
| Cui, Z | 1 |
| He, S | 2 |
| Wen, F | 1 |
| Lu, L | 1 |
| Xu, L | 2 |
| Wu, H | 1 |
| Wu, S | 1 |
| Kim, K | 1 |
| Lee, K | 2 |
| Cho, S | 1 |
| Kang, DU | 1 |
| Park, S | 1 |
| Kang, Y | 1 |
| Kim, H | 7 |
| Choe, G | 1 |
| Moon, KC | 1 |
| Lee, KS | 1 |
| Park, JH | 1 |
| Hong, C | 1 |
| Nateghi, R | 1 |
| Pourakpour, F | 1 |
| Wang, X | 2 |
| Yang, S | 1 |
| Jahromi, SAF | 1 |
| Khani, A | 1 |
| Kim, HR | 1 |
| Choi, DH | 1 |
| Han, CH | 1 |
| Kwak, JT | 1 |
| Zhang, F | 1 |
| Han, B | 1 |
| Ho, DJ | 1 |
| Kang, GH | 6 |
| Chun, SY | 1 |
| Jeong, WK | 1 |
| Park, P | 1 |
| Choi, J | 2 |
| Mohammadpour, S | 1 |
| Goodarzi, HR | 1 |
| Jafarinia, M | 1 |
| Porhoseingholi, MA | 1 |
| Nazemalhosseini-Mojarad, E | 1 |
| Johansen, AFB | 1 |
| Kassentoft, CG | 1 |
| Knudsen, M | 1 |
| Laursen, MB | 1 |
| Madsen, AH | 1 |
| Iversen, LH | 1 |
| Sunesen, KG | 1 |
| Rasmussen, MH | 1 |
| Andersen, CL | 1 |
| Alwers, E | 1 |
| Jansen, L | 1 |
| Bläker, H | 1 |
| Kloor, M | 2 |
| Tagscherer, KE | 1 |
| Roth, W | 1 |
| Boakye, D | 1 |
| Herpel, E | 1 |
| Grüllich, C | 1 |
| Chang-Claude, J | 1 |
| Brenner, H | 1 |
| Hoffmeister, M | 1 |
| Tougeron, D | 1 |
| Sueur, B | 1 |
| Zaanan, A | 5 |
| de la Fouchardiére, C | 2 |
| Sefrioui, D | 1 |
| Lecomte, T | 1 |
| Aparicio, T | 1 |
| Des Guetz, G | 3 |
| Artru, P | 1 |
| Hautefeuille, V | 1 |
| Coriat, R | 1 |
| Moulin, V | 1 |
| Locher, C | 1 |
| Touchefeu, Y | 1 |
| Lecaille, C | 2 |
| Goujon, G | 1 |
| Ferru, A | 1 |
| Evrard, C | 1 |
| Chautard, R | 1 |
| Gentilhomme, L | 1 |
| Vernerey, D | 1 |
| Taieb, J | 5 |
| André, T | 4 |
| Henriques, J | 1 |
| Das, S | 2 |
| Allen, A | 1 |
| Di Bartolomeo, M | 1 |
| Morano, F | 2 |
| Raimondi, A | 1 |
| Miceli, R | 1 |
| Corallo, S | 2 |
| Tamborini, E | 1 |
| Perrone, F | 1 |
| Antista, M | 1 |
| Niger, M | 1 |
| Pellegrinelli, A | 1 |
| Randon, G | 1 |
| Pagani, F | 1 |
| Martinetti, A | 1 |
| Fucà, G | 1 |
| Pietrantonio, F | 2 |
| Sastre, J | 1 |
| Orden, V | 1 |
| Martínez, A | 1 |
| Bando, I | 1 |
| Balbín, M | 1 |
| Bellosillo, B | 1 |
| Palanca, S | 1 |
| Peligros Gomez, MI | 1 |
| Mediero, B | 1 |
| Llovet, P | 1 |
| Moral, VM | 1 |
| Viéitez, JM | 1 |
| García-Alfonso, P | 1 |
| Calle, SG | 1 |
| Ortiz-Morales, MJ | 1 |
| Salud, A | 1 |
| Quintero, G | 1 |
| Lopez, C | 1 |
| Díaz-Rubio, E | 1 |
| Aranda, E | 1 |
| Antoniotti, C | 1 |
| Borelli, B | 1 |
| Rossini, D | 1 |
| Salvatore, L | 1 |
| Lonardi, S | 3 |
| Marmorino, F | 1 |
| Tamberi, S | 1 |
| Tortora, G | 1 |
| Bergamo, F | 1 |
| Brunella, DS | 1 |
| Boccaccino, A | 1 |
| Grassi, E | 1 |
| Racca, P | 1 |
| Tamburini, E | 1 |
| Aprile, G | 1 |
| Moretto, R | 1 |
| Boni, L | 1 |
| Falcone, A | 1 |
| Cremolini, C | 1 |
| Liu, J | 1 |
| Wang, B | 1 |
| Fang, W | 1 |
| Malla, SB | 1 |
| Fisher, DJ | 1 |
| Domingo, E | 1 |
| Blake, A | 1 |
| Hassanieh, S | 1 |
| Redmond, KL | 1 |
| Richman, SD | 2 |
| Youdell, M | 1 |
| Walker, SM | 1 |
| Logan, GE | 1 |
| Chatzipli, A | 1 |
| Amirkhah, R | 1 |
| Humphries, MP | 1 |
| Craig, SG | 1 |
| McDermott, U | 1 |
| Seymour, MT | 2 |
| Morton, DG | 1 |
| Quirke, P | 2 |
| West, NP | 1 |
| Salto-Tellez, M | 2 |
| Kennedy, RD | 2 |
| Johnston, PG | 1 |
| Tomlinson, I | 2 |
| Koelzer, VH | 1 |
| Campo, L | 1 |
| Kaplan, RS | 1 |
| Longley, DB | 1 |
| Lawler, M | 1 |
| Maughan, TS | 1 |
| Brown, LC | 1 |
| Dunne, PD | 1 |
| Beypinar, I | 1 |
| Demir, H | 1 |
| Araz, M | 1 |
| Baykara, M | 1 |
| Aykan, NF | 1 |
| Shiu, KK | 1 |
| Kim, TW | 2 |
| Jensen, BV | 1 |
| Jensen, LH | 2 |
| Punt, C | 1 |
| Smith, D | 1 |
| Garcia-Carbonero, R | 1 |
| Benavides, M | 1 |
| Gibbs, P | 1 |
| Rivera, F | 1 |
| Elez, E | 1 |
| Bendell, J | 1 |
| Le, DT | 1 |
| Yoshino, T | 3 |
| Van Cutsem, E | 4 |
| Yang, P | 1 |
| Farooqui, MZH | 1 |
| Marinello, P | 1 |
| Diaz, LA | 1 |
| Fiskum, J | 1 |
| Yothers, G | 3 |
| Goldberg, R | 1 |
| Alberts, S | 2 |
| Allegra, C | 2 |
| de Gramont, A | 3 |
| Seitz, JF | 1 |
| O'Connell, M | 1 |
| Haller, D | 1 |
| Wolmark, N | 2 |
| Erlichman, C | 1 |
| Kerr, R | 2 |
| Grothey, A | 4 |
| Sinicrope, FA | 6 |
| Shi, Q | 4 |
| Cai, Z | 1 |
| Ma, J | 1 |
| Li, S | 1 |
| Fingerhut, A | 1 |
| Zang, L | 1 |
| Yan, C | 1 |
| Liu, W | 1 |
| Zhu, Z | 1 |
| Zheng, M | 1 |
| Noepel-Duennebacke, S | 1 |
| Juette, H | 1 |
| Schulmann, K | 3 |
| Graeven, U | 3 |
| Porschen, R | 4 |
| Stoehlmacher, J | 1 |
| Hegewisch-Becker, S | 1 |
| Raulf, A | 1 |
| Arnold, D | 3 |
| Reinacher-Schick, A | 4 |
| Tannapfel, A | 3 |
| Botta, GP | 1 |
| Kato, S | 1 |
| Patel, H | 1 |
| Fanta, P | 1 |
| Lee, S | 1 |
| Okamura, R | 1 |
| Kurzrock, R | 1 |
| Bayir Garbioglu, D | 1 |
| Demir, N | 1 |
| Ozel, C | 1 |
| Avci, H | 1 |
| Dincer, M | 1 |
| Zhang, L | 1 |
| Zhao, J | 2 |
| Yu, B | 1 |
| Song, X | 1 |
| Sun, G | 1 |
| Han, L | 1 |
| Wang, L | 1 |
| Dong, S | 1 |
| Shi, L | 1 |
| Li, X | 4 |
| Wu, Z | 2 |
| Nie, J | 2 |
| Guo, M | 1 |
| Mei, Q | 2 |
| Han, W | 2 |
| Venook, AP | 1 |
| Cardin, D | 1 |
| Murcia, O | 1 |
| Juárez, M | 1 |
| Rodríguez-Soler, M | 1 |
| Hernández-Illán, E | 1 |
| Giner-Calabuig, M | 1 |
| Alustiza, M | 1 |
| Egoavil, C | 1 |
| Castillejo, A | 1 |
| Alenda, C | 2 |
| Barberá, V | 1 |
| Mangas-Sanjuan, C | 1 |
| Yuste, A | 1 |
| Bujanda, L | 2 |
| Clofent, J | 2 |
| Andreu, M | 3 |
| Castells, A | 3 |
| Llor, X | 3 |
| Zapater, P | 2 |
| Jover, R | 3 |
| Chu, JN | 1 |
| Ostvar, S | 1 |
| Torchia, JA | 1 |
| Reynolds, KL | 1 |
| Tramontano, A | 1 |
| Gainor, JF | 1 |
| Chung, DC | 2 |
| Clark, JW | 2 |
| Hur, C | 2 |
| Stintzing, S | 1 |
| Chouhan, H | 1 |
| Sammour, T | 1 |
| Thomas, ML | 1 |
| Moore, JW | 1 |
| Mondaca, S | 1 |
| Yoon, SS | 1 |
| Strong, VE | 1 |
| Ku, GY | 1 |
| Ilson, DH | 1 |
| Greally, M | 1 |
| Janjigian, YY | 1 |
| Battaglin, F | 1 |
| Naseem, M | 1 |
| Lenz, HJ | 3 |
| Salem, ME | 1 |
| Bottarelli, L | 2 |
| De' Angelis, GL | 1 |
| Azzoni, C | 2 |
| Di Mario, F | 1 |
| De' Angelis, N | 1 |
| Leandro, G | 1 |
| Fornaroli, F | 1 |
| Gaiani, F | 1 |
| Negri, F | 1 |
| Song, M | 1 |
| Ou, FS | 1 |
| Zemla, TJ | 1 |
| Hull, MA | 1 |
| Limburg, PJ | 1 |
| Alberts, SR | 2 |
| Giovannucci, EL | 1 |
| Van Blarigan, EL | 1 |
| Chan, AT | 1 |
| Soefje, SA | 1 |
| Zhao, F | 1 |
| Yuan, X | 1 |
| Ren, D | 1 |
| Shen, G | 1 |
| Wang, Z | 1 |
| Zheng, F | 1 |
| Ahmad, R | 1 |
| Ma, Z | 1 |
| Oh, HJ | 1 |
| Bae, JM | 4 |
| Wen, X | 2 |
| Jung, S | 1 |
| Kim, Y | 1 |
| Kim, KJ | 1 |
| Cho, NY | 3 |
| Kim, JH | 3 |
| Han, SW | 5 |
| Kim, TY | 6 |
| Lee, DW | 2 |
| Cha, Y | 1 |
| Kim, HP | 1 |
| Lyu, J | 1 |
| Han, H | 2 |
| Jang, H | 2 |
| Bang, D | 2 |
| Won, JK | 1 |
| Jeong, SY | 3 |
| Park, KJ | 3 |
| Gbolahan, O | 1 |
| Hashemi-Sadraei, N | 1 |
| O'Neil, B | 1 |
| Pederson, L | 1 |
| Li, P | 1 |
| Fang, YJ | 1 |
| Li, F | 1 |
| Ou, QJ | 1 |
| Chen, G | 1 |
| Ma, G | 1 |
| Oh, SY | 1 |
| Kim, DY | 1 |
| Kim, YB | 1 |
| Suh, KW | 1 |
| Kim, SH | 2 |
| Shin, SJ | 1 |
| Lee, KY | 1 |
| Kim, TI | 2 |
| Kang, DR | 1 |
| Hur, H | 1 |
| Min, BS | 2 |
| Kim, NK | 2 |
| Chung, HC | 1 |
| Roh, JK | 1 |
| Ahn, JB | 1 |
| Negri, FV | 2 |
| Campanini, N | 2 |
| Mandolesi, A | 2 |
| Wotherspoon, A | 2 |
| Cunningham, D | 3 |
| Scartozzi, M | 2 |
| Cascinu, S | 3 |
| Tinelli, C | 1 |
| Silini, EM | 1 |
| Ardizzoni, A | 2 |
| Ogino, S | 3 |
| Liao, X | 1 |
| Imamura, Y | 1 |
| Yamauchi, M | 1 |
| McCleary, NJ | 1 |
| Ng, K | 2 |
| Niedzwiecki, D | 3 |
| Saltz, LB | 3 |
| Mayer, RJ | 3 |
| Whittom, R | 1 |
| Benson, AB | 2 |
| Mowat, RB | 1 |
| Spiegelman, D | 1 |
| Goldberg, RM | 4 |
| Bertagnolli, MM | 3 |
| Fuchs, CS | 3 |
| Lagrange, A | 2 |
| Marisa, L | 2 |
| Buhard, O | 2 |
| Guilloux, A | 2 |
| Wanherdrick, K | 2 |
| Dorard, C | 2 |
| Taieb, A | 1 |
| Saget, A | 1 |
| Loh, M | 1 |
| Soong, R | 1 |
| Zeps, N | 1 |
| Platell, C | 1 |
| Mews, A | 1 |
| Iacopetta, B | 1 |
| De Thonel, A | 2 |
| Seigneuric, R | 1 |
| Marcion, G | 1 |
| Chapusot, C | 1 |
| Lepage, C | 1 |
| Bouvier, AM | 1 |
| Gaub, MP | 2 |
| Milano, G | 2 |
| Selves, J | 2 |
| Senet, P | 1 |
| Delarue, P | 1 |
| Arzouk, H | 1 |
| Lacoste, C | 1 |
| Coquelle, A | 1 |
| Bengrine-Lefèvre, L | 2 |
| Tournigand, C | 2 |
| Lefèvre, JH | 2 |
| Parc, Y | 3 |
| Biard, DS | 1 |
| Fléjou, JF | 3 |
| Garrido, C | 2 |
| Klingbiel, D | 2 |
| Saridaki, Z | 2 |
| Roth, AD | 3 |
| Bosman, FT | 2 |
| Delorenzi, M | 3 |
| Tejpar, S | 4 |
| Nöpel-Dünnebacke, S | 1 |
| Schmiegel, W | 2 |
| Stadler, ZK | 1 |
| Kim, SY | 2 |
| Choi, YY | 1 |
| An, JY | 2 |
| Shin, HB | 1 |
| Jo, A | 1 |
| Choi, H | 1 |
| Seo, SH | 1 |
| Bang, HJ | 1 |
| Cheong, JH | 2 |
| Hyung, WJ | 2 |
| Noh, SH | 2 |
| Yang, L | 1 |
| Sun, Y | 1 |
| Huang, XE | 1 |
| Yu, DS | 1 |
| Zhou, JN | 1 |
| Zhou, X | 1 |
| Li, DZ | 1 |
| Guan, X | 1 |
| Neumann, JH | 1 |
| Jung, A | 2 |
| Kirchner, T | 3 |
| Webber, EM | 1 |
| Kauffman, TL | 1 |
| O'Connor, E | 1 |
| Goddard, KA | 1 |
| Liao, D | 1 |
| Bai, M | 1 |
| Fu, X | 1 |
| Pectasides, D | 1 |
| Karavasilis, V | 1 |
| Papaxoinis, G | 1 |
| Gourgioti, G | 1 |
| Makatsoris, T | 1 |
| Raptou, G | 1 |
| Vrettou, E | 1 |
| Sgouros, J | 1 |
| Samantas, E | 1 |
| Basdanis, G | 1 |
| Papakostas, P | 1 |
| Bafaloukos, D | 1 |
| Kotoula, V | 1 |
| Kalofonos, HP | 1 |
| Scopa, CD | 1 |
| Pentheroudakis, G | 1 |
| Fountzilas, G | 1 |
| Kawakami, H | 1 |
| Zhao, Z | 1 |
| Yang, Y | 1 |
| O'Connell, D | 1 |
| Zhang, X | 1 |
| Oh, S | 1 |
| Ma, B | 1 |
| Lee, JH | 1 |
| Zhang, T | 1 |
| Varghese, B | 1 |
| Yip, J | 1 |
| Dolatshahi Pirooz, S | 1 |
| Li, M | 1 |
| Zhang, Y | 1 |
| Li, GM | 1 |
| Ellen Martin, S | 1 |
| Machida, K | 1 |
| Liang, C | 1 |
| Ágoston, EI | 1 |
| Baranyai, Z | 1 |
| Dede, K | 1 |
| Bodoky, G | 1 |
| Kulka, J | 1 |
| Bursics, A | 1 |
| Harsányi, L | 1 |
| Szász, AM | 1 |
| Sena, P | 1 |
| Mariani, F | 1 |
| Mancini, S | 1 |
| Benincasa, M | 1 |
| Magnani, G | 1 |
| Pedroni, M | 1 |
| Palumbo, C | 1 |
| Roncucci, L | 1 |
| Giampieri, R | 1 |
| Maccaroni, E | 1 |
| Del Prete, M | 1 |
| Andrikou, K | 1 |
| Faloppi, L | 1 |
| Bittoni, A | 1 |
| Bianconi, M | 1 |
| Scarpelli, M | 1 |
| Bracci, R | 1 |
| He, EY | 1 |
| Hawkins, NJ | 1 |
| Mak, G | 1 |
| Roncolato, F | 1 |
| Goldstein, D | 1 |
| Liauw, W | 1 |
| Clingan, P | 1 |
| Chin, M | 1 |
| Ward, RL | 1 |
| Chen, D | 1 |
| Song, YS | 1 |
| Rhee, YY | 1 |
| Lee, TH | 1 |
| Sargent, DJ | 4 |
| Sehdev, A | 1 |
| Cramer, HM | 1 |
| Ibrahim, AA | 1 |
| Younger, AE | 1 |
| O'Neil, BH | 1 |
| Srdjan, M | 1 |
| Jadranka, A | 1 |
| Ivan, D | 1 |
| Branimir, Z | 1 |
| Daniela, B | 1 |
| Petar, S | 1 |
| Velimir, M | 1 |
| Zoran, K | 1 |
| Hasson, RM | 1 |
| Ye, C | 1 |
| Redston, M | 2 |
| Compton, CC | 2 |
| Colacchio, TA | 1 |
| Warren, RS | 2 |
| Kim, JE | 1 |
| Hong, YS | 1 |
| Kim, HJ | 1 |
| Kim, KP | 1 |
| Lim, SB | 1 |
| Park, IJ | 1 |
| Kim, CW | 1 |
| Yoon, YS | 1 |
| Yu, CS | 1 |
| Kim, JC | 1 |
| Jang, MH | 1 |
| Kim, S | 1 |
| Hwang, DY | 1 |
| Kim, WY | 1 |
| Lim, SD | 1 |
| Kim, WS | 1 |
| Hwang, TS | 1 |
| Han, HS | 1 |
| Le Malicot, K | 1 |
| Penault-Llorca, F | 1 |
| Bouché, O | 1 |
| Tabernero, J | 1 |
| Mini, E | 1 |
| Folprecht, G | 1 |
| Luc Van Laethem, J | 1 |
| Emile, JF | 1 |
| Laurent Puig, P | 1 |
| Copija, A | 1 |
| Waniczek, D | 1 |
| Witkoś, A | 1 |
| Walkiewicz, K | 1 |
| Nowakowska-Zajdel, E | 1 |
| Park, BS | 1 |
| Kim, HS | 1 |
| Smyth, EC | 1 |
| Peckitt, C | 1 |
| Gonzalez, D | 1 |
| Hulkki-Wilson, S | 1 |
| Eltahir, Z | 1 |
| Fassan, M | 1 |
| Rugge, M | 1 |
| Valeri, N | 1 |
| Okines, A | 1 |
| Hewish, M | 1 |
| Allum, W | 1 |
| Stenning, S | 1 |
| Nankivell, M | 1 |
| Langley, R | 1 |
| Müller, CI | 1 |
| Andre, N | 1 |
| Arkenau, H | 1 |
| Hahn, SA | 1 |
| Schmoll, SH | 1 |
| Cubiella, J | 1 |
| Balaguer, F | 1 |
| Sempere, L | 1 |
| Xicola, RM | 1 |
| Reñé, JM | 1 |
| Bessa, X | 1 |
| Morillas, JD | 1 |
| Nicolás-Pérez, D | 1 |
| Pons, E | 1 |
| Payá, A | 1 |
| Jin, H | 1 |
| Liu, X | 1 |
| Li, VK | 1 |
| Ding, Y | 1 |
| Yun, S | 1 |
| Liu, F | 1 |
| Zhou, S | 1 |
| Song, Y | 1 |
| Ni, M | 1 |
| Jensen, SA | 1 |
| Vainer, B | 1 |
| Kruhøffer, M | 1 |
| Sørensen, JB | 1 |
| Koopman, M | 1 |
| Kortman, GA | 1 |
| Mekenkamp, L | 1 |
| Ligtenberg, MJ | 1 |
| Hoogerbrugge, N | 1 |
| Antonini, NF | 1 |
| Punt, CJ | 1 |
| van Krieken, JH | 1 |
| Jain, AK | 1 |
| Motil, KJ | 1 |
| Olutoye, OO | 1 |
| Cope-Yokoyama, S | 1 |
| Egler, RA | 1 |
| Tatevian, N | 1 |
| Hahn, HP | 1 |
| Hall, M | 1 |
| Damas, B | 1 |
| Jewell, SD | 1 |
| Uzzan, B | 2 |
| Nicolas, P | 2 |
| Schischmanoff, O | 1 |
| Morere, JF | 2 |
| Walther, A | 1 |
| Johnstone, E | 1 |
| Swanton, C | 1 |
| Midgley, R | 1 |
| Kerr, D | 1 |
| Oki, E | 1 |
| Kakeji, Y | 2 |
| Zhao, Y | 1 |
| Yoshida, R | 1 |
| Ando, K | 1 |
| Masuda, T | 1 |
| Ohgaki, K | 1 |
| Morita, M | 2 |
| Maehara, Y | 2 |
| Yashiro, M | 1 |
| Inoue, T | 1 |
| Nishioka, N | 1 |
| Matsuoka, T | 1 |
| Boland, CR | 1 |
| Hirakawa, K | 1 |
| Yan, P | 2 |
| Fiocca, R | 2 |
| Dietrich, D | 1 |
| Roth, A | 1 |
| Cuilliere-Dartigues, P | 1 |
| Louvet, C | 2 |
| Tiret, E | 2 |
| Dumont, S | 1 |
| Gayet, B | 1 |
| Validire, P | 1 |
| Praz, F | 1 |
| Chambers, P | 1 |
| Elliott, F | 1 |
| Daly, CL | 1 |
| Meade, AM | 1 |
| Taylor, G | 1 |
| Barrett, JH | 1 |
| Kucherlapati, MH | 1 |
| Nguyen, AA | 1 |
| Clark, AB | 1 |
| Hou, H | 1 |
| Rosulek, A | 1 |
| Li, H | 2 |
| Yang, K | 1 |
| Fan, K | 1 |
| Lipkin, M | 1 |
| Bronson, RT | 1 |
| Jelicks, L | 1 |
| Kunkel, TA | 1 |
| Kucherlapati, R | 1 |
| Edelmann, W | 1 |
| Kim, ST | 2 |
| Lee, J | 2 |
| Park, SH | 2 |
| Park, JO | 2 |
| Lim, HY | 2 |
| Kang, WK | 2 |
| Kim, JY | 2 |
| Kim, YH | 2 |
| Chang, DK | 2 |
| Rhee, PL | 2 |
| Kim, DS | 2 |
| Yun, H | 2 |
| Cho, YB | 2 |
| Kim, HC | 2 |
| Yun, SH | 2 |
| Chun, HK | 2 |
| Lee, WY | 2 |
| Park, YS | 2 |
| Donada, M | 1 |
| Bonin, S | 1 |
| Nardon, E | 1 |
| De Pellegrin, A | 1 |
| Decorti, G | 1 |
| Stanta, G | 1 |
| Trarbach, T | 1 |
| Ridwelski, K | 1 |
| Bruch, HP | 1 |
| Kubicka, S | 1 |
| Schmoll, HJ | 1 |
| Schrag, D | 1 |
| Guastadisegni, C | 1 |
| Colafranceschi, M | 1 |
| Ottini, L | 1 |
| Dogliotti, E | 1 |
| Xu, JM | 1 |
| Dietmaier, W | 1 |
| Lombardo, Y | 1 |
| Scopelliti, A | 1 |
| Cammareri, P | 1 |
| Todaro, M | 1 |
| Iovino, F | 1 |
| Ricci-Vitiani, L | 1 |
| Gulotta, G | 1 |
| Dieli, F | 1 |
| de Maria, R | 1 |
| Stassi, G | 1 |
| Mariani, P | 2 |
| Bennamoun, M | 1 |
| Boisseau, A | 1 |
| Sastre, X | 1 |
| Cucherousset, J | 1 |
| Lagorce, C | 1 |
| Schischmanoff, PO | 1 |
| Kawakami, K | 1 |
| Matsunoki, A | 1 |
| Kaneko, M | 1 |
| Saito, K | 1 |
| Watanabe, G | 1 |
| Minamoto, T | 1 |
| Lombardi, L | 1 |
| Morelli, F | 1 |
| Cinieri, S | 1 |
| Santini, D | 1 |
| Silvestris, N | 1 |
| Fazio, N | 1 |
| Orlando, L | 1 |
| Tonini, G | 1 |
| Colucci, G | 1 |
| Maiello, E | 1 |
| Bosman, F | 2 |
| Foster, NR | 1 |
| Thibodeau, SN | 1 |
| Marsoni, S | 1 |
| Monges, G | 1 |
| Labianca, R | 2 |
| Kim, GP | 1 |
| Moore, MJ | 1 |
| Gallinger, S | 1 |
| Chan, JY | 1 |
| Ong, CW | 1 |
| Duldulao, MP | 1 |
| Lee, W | 1 |
| Le, M | 1 |
| Chen, Z | 1 |
| Li, W | 2 |
| Wang, J | 1 |
| Gao, H | 1 |
| Kim, J | 1 |
| Garcia-Aguilar, J | 1 |
| Jego, G | 1 |
| Joly, AL | 1 |
| Gobbo, J | 1 |
| Penard-Lacronique, V | 1 |
| Zouali, H | 1 |
| Tubacher, E | 1 |
| Kirzin, S | 1 |
| Etienne-Grimaldi, MC | 1 |
| Hong, SP | 1 |
| Cheon, JH | 1 |
| Kim, WH | 1 |
| Adibe, OO | 1 |
| Sharp, RJ | 1 |
| Tikidzhieva, A | 1 |
| Benner, A | 1 |
| Michel, S | 1 |
| Formentini, A | 1 |
| Link, KH | 1 |
| Dippold, W | 1 |
| von Knebel Doeberitz, M | 1 |
| Kornmann, M | 1 |
| Nakanishi, R | 1 |
| Kitao, H | 1 |
| Fujinaka, Y | 1 |
| Yamashita, N | 2 |
| Iimori, M | 1 |
| Tokunaga, E | 1 |
| Julien, S | 1 |
| Merino-Trigo, A | 1 |
| Lacroix, L | 1 |
| Pocard, M | 1 |
| Goéré, D | 1 |
| Landron, S | 1 |
| Bigot, L | 1 |
| Nemati, F | 1 |
| Dartigues, P | 1 |
| Weiswald, LB | 1 |
| Lantuas, D | 1 |
| Morgand, L | 1 |
| Pham, E | 1 |
| Gonin, P | 1 |
| Dangles-Marie, V | 1 |
| Job, B | 1 |
| Dessen, P | 1 |
| Bruno, A | 1 |
| Pierré, A | 1 |
| De Thé, H | 1 |
| Soliman, H | 1 |
| Nunes, M | 1 |
| Lardier, G | 1 |
| Calvet, L | 1 |
| Demers, B | 1 |
| Prévost, G | 1 |
| Vrignaud, P | 1 |
| Roman-Roman, S | 1 |
| Duchamp, O | 1 |
| Berthet, C | 1 |
| Lee, HJ | 1 |
| Lee, KH | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Bang, YJ | 1 |
| Park, JG | 1 |
| d'Ario, G | 1 |
| Cisar, L | 1 |
| Nordlinger, B | 1 |
| Buecher, B | 1 |
| Cacheux, W | 1 |
| Rouleau, E | 1 |
| Dieumegard, B | 1 |
| Mitry, E | 1 |
| Lièvre, A | 1 |
| Desselle, F | 1 |
| Verset, G | 1 |
| Polus, M | 1 |
| Louis, E | 1 |
| Van Daele, D | 1 |
| Warusavitarne, J | 1 |
| Ramanathan, P | 1 |
| Kaufman, A | 1 |
| Robinson, BG | 1 |
| Schnitzler, M | 1 |
| Lamberti, C | 1 |
| Lundin, S | 1 |
| Bogdanow, M | 1 |
| Pagenstecher, C | 1 |
| Friedrichs, N | 1 |
| Büttner, R | 1 |
| Sauerbruch, T | 1 |
| Sun, XW | 1 |
| Zhan, YQ | 1 |
| Li, JT | 1 |
| Chen, XJ | 1 |
| Zhang, RH | 1 |
| Xu, DZ | 1 |
| Kawasaki, T | 1 |
| Ryan, DP | 1 |
| Kulke, MH | 1 |
| Enzinger, PC | 1 |
| Wolpin, BM | 1 |
| Loda, M | 1 |
| Nehls, O | 1 |
| Okech, T | 1 |
| Hsieh, CJ | 1 |
| Enzinger, T | 1 |
| Sarbia, M | 1 |
| Borchard, F | 1 |
| Gruenagel, HH | 1 |
| Gaco, V | 1 |
| Hass, HG | 1 |
| Arkenau, HT | 1 |
| Hartmann, JT | 1 |
| Gregor, M | 1 |
| Klump, B | 1 |
| Danenberg, KD | 1 |
| Danenberg, PV | 1 |
| Jakobsen, A | 1 |
| Choi, MY | 1 |
| Lauwers, GY | 1 |
| Willett, CG | 1 |
| Napieralski, R | 1 |
| Ott, K | 1 |
| Kremer, M | 1 |
| Becker, K | 1 |
| Boulesteix, AL | 1 |
| Lordick, F | 1 |
| Siewert, JR | 1 |
| Höfler, H | 1 |
| Keller, G | 1 |
| Bendardaf, R | 1 |
| Lamlum, H | 1 |
| Ristamäki, R | 1 |
| Korkeila, E | 1 |
| Syrjänen, K | 1 |
| Pyrhönen, S | 1 |
| Camisa, R | 1 |
| Pucci, F | 1 |
| Bui, S | 1 |
| Ceccon, G | 1 |
| Martinelli, R | 1 |
| Fumagalli, M | 1 |
| Losardo, PL | 1 |
| Crafa, P | 1 |
| Bordi, C | 1 |
| Wilson, PM | 1 |
| Ladner, RD | 1 |
| Shankaran, V | 1 |
| Wisinski, KB | 1 |
| Mulcahy, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.[NCT01640405] | Phase 3 | 350 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells[NCT01640444] | Phase 2 | 240 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients.[NCT03721653] | Phase 2 | 218 participants (Actual) | Interventional | 2018-11-30 | Completed | ||
| Safety and Efficacy of mFOLFOX6+ Bevacizumab+PD-1 Monoclonal Antibody Treatment Combinations in Patients With Local Advanced Microsatellite Stability Colorectal Cancer --an Open Label, Multicenter, Prospective Phase Ⅱ Study (BASKETII)[NCT04895137] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)[NCT06141369] | 21 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Efficacy and Safety of Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin in pMMR/MSS Locally Advanced Middle and Low Rectal Cancer: An Open, Multi-center, Prospective, Single-arm Phase II Clinical Study[NCT06056804] | Phase 2 | 20 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)[NCT02563002] | Phase 3 | 307 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Combination of Sintilimab，Celecoxib and Regorafenib in Mismatch Repair (MMR) Proficient Refractory Advanced Colorectal Cancer Without Liver Metastasis：a Single Arm Phase II SINCERE Study.[NCT05933980] | Phase 2 | 33 participants (Anticipated) | Interventional | 2023-08-20 | Not yet recruiting | ||
| Multi-center, Non-interventional, Prospective Registry Study on the Treatment of Solid Tumors With Mismatch Repair Deficiency or Microsatellite Instability[NCT06004713] | 190 participants (Anticipated) | Observational | 2023-10-07 | Recruiting | |||
| METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin[NCT05504252] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-10-05 | Recruiting | ||
| Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer[NCT00275210] | Phase 3 | 2,246 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab[NCT00265811] | Phase 3 | 2,559 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931] | Phase 3 | 2,472 participants (Anticipated) | Interventional | 2000-02-29 | Completed | ||
| A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma [NCT00096278] | Phase 3 | 2,710 participants (Actual) | Interventional | 2004-09-15 | Completed | ||
| A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274] | Phase 3 | 3,397 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regime[NCT00112918] | Phase 3 | 3,451 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)[NCT02478931] | 10,000 participants (Anticipated) | Observational | 2013-09-05 | Recruiting | |||
| Multicenter Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone As Adjuvant Treatment Of Stage III Colon Cancer[NCT00026273] | Phase 3 | 0 participants | Interventional | 2001-01-31 | Completed | ||
| Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer[NCT00003835] | Phase 3 | 1,260 participants (Anticipated) | Interventional | 1999-05-31 | Completed | ||
| Epidemiological and Molecular Colorectal Cancer Registry[NCT02781337] | 2,100 participants (Anticipated) | Observational [Patient Registry] | 2012-05-31 | Recruiting | |||
| PD-1 Antibody Adjuvant Therapy for Patients With MSI-H Advanced Gastric or Gastroesophageal Junction Cancer After Radical Surgery With D2 Dissection: a Phase II Single-center, Three-arm, Randomized Controlled Clinical Trial[NCT05468138] | Phase 2 | 141 participants (Anticipated) | Interventional | 2022-08-25 | Not yet recruiting | ||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing: A Randomized Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer[NCT00008060] | Phase 3 | 0 participants | Interventional | 2000-05-31 | Completed | ||
| Timing of Rectal Cancer Response to Chemoradiation[NCT00335816] | Phase 2 | 248 participants (Anticipated) | Interventional | 2008-08-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab | 21 |
| Standard of Care (SOC) | 20 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab | 149 |
| Standard of Care (SOC) | 142 |
ORR was defined as the percentage of the participants who experienced a Complete Response (CR; disappearance of all target lesions) or a Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions) and was assessed using RECIST 1.1 as assessed by the central imaging vendor. The percentage of participants who experienced a CR or PR was presented for the first course of study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab | 45.1 |
| Standard of Care (SOC) | 33.1 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of analysis were censored at the date of last known contact. HR and associated 95% CIs from a Cox proportional hazard model with Efron's method of tie handling and with a single treatment covariate was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab | NA |
| Standard of Care (SOC) | 36.7 |
PFS was defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 based on blinded central imaging vendor review or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Hazards ratio (HR) and associated 95% confidence intervals (CIs) from a Cox proportional hazard model with Efron's method of tie handling and with a single treatment covariate was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab | 16.5 |
| Standard of Care (SOC) | 8.2 |
Where events are defined as recurrence, second primary cancer, or death from any cause (NCT00096278)
Timeframe: 3 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil | 75.5 |
| Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab | 77.4 |
Percentage of patients who did not experience an event where events are defined as death from any cause. (NCT00096278)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (mFOLFOX6) | 77.6 |
| Arm II (Bevacizumab, mFOLFOX6) | 78.7 |
"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 67.1 |
| Mutant KRAS Arm D | 65.0 |
"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 74.6 |
| Wild-type KRAS Arm D | 71.5 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 87.9 |
| Mutant KRAS Arm D | 82.7 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 87.3 |
| Wild-type KRAS Arm D | 85.6 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Mutant KRAS Arm A | 55.6 |
| Mutant KRAS Arm D | 72.3 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Wild-type KRAS Arm A | 51.1 |
| Wild-type KRAS Arm D | 73.3 |
Disease-free survival (DFS) was defined as the time from the date of randomization to the time of a recurrence, a new occurrence of colorectal cancer or death due to any cause, whichever occurred first. Patients without an event were censored at the last date the patient was known to be disease-free. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Patients with no tumor assessments after baseline but still alive at the time of the clinical cut-off were censored at day 1. (NCT00112918)
Timeframe: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | months (Median) |
|---|---|
| FOLFOX4 | NA |
| FOLFOX4 + Bv | NA |
| XELOX+Bv | NA |
Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the analysis were censored at the date they were last known to be alive. (NCT00112918)
Timeframe: From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | months (Median) |
|---|---|
| FOLFOX4 | NA |
| FOLFOX4 + Bv | NA |
| XELOX+Bv | NA |
Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the clinical cut-off date (30 June 2012) were censored at the date they were last known to be alive. (NCT00112918)
Timeframe: From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).
| Intervention | months (Median) |
|---|---|
| FOLFOX4 | NA |
| FOLFOX4 + Bv | NA |
| XELOX+Bv | NA |
A disease-free survival (DFS) event was composed of a recurrence, a new occurrence of colorectal cancer or death due to any cause. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Triggering events for DFS are reported; a patient can have both recurrence and a new occurrence of colon cancer. (NCT00112918)
Timeframe: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Patients with a DFS event | Recurrence | New Occurrence | Death | Patients without events | |
| FOLFOX4 | 237 | 219 | 3 | 17 | 718 |
| FOLFOX4 + Bv | 280 | 253 | 8 | 21 | 680 |
| XELOX+Bv | 253 | 223 | 6 | 25 | 699 |
An overall survival event was death due to any cause. (NCT00112918)
Timeframe: From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | participants (Number) | |
|---|---|---|
| Patients with events | Patients without events | |
| FOLFOX4 | 115 | 840 |
| FOLFOX4 + Bv | 151 | 809 |
| XELOX+Bv | 145 | 807 |
An overall survival event was death due to any cause. (NCT00112918)
Timeframe: From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).
| Intervention | participants (Number) | |
|---|---|---|
| Patients with events | Patients without events | |
| FOLFOX4 | 161 | 794 |
| FOLFOX4 + Bv | 202 | 758 |
| XELOX+Bv | 182 | 770 |
29 reviews available for fluorouracil and Microsatellite Instability
| Article | Year |
|---|---|
Systematic review and meta-analysis of tumour microsatellite-instability status as a predictor of response to fluorouracil-based adjuvant chemotherapy in colorectal cancer.
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Instability; Micr | 2022 |
Adjuvant treatment of colon cancer with microsatellite instability - the state of the art.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; DNA Mismatch Repair; Fluorouracil; | 2022 |
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Colonic Neo | 2022 |
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITA
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Chemotherapy, Adjuvant; Cisplatin; Do | 2020 |
Harnessing the Immune System in Pancreatic Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2018 |
Recent advances in understanding colorectal cancer.
Topics: Antibodies; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Microsatellite Instability; | 2018 |
[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplas | 2019 |
Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA Mismatch Repair; Fluorour | 2018 |
Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Biomarkers, Tumor; Chemoradiotherapy; Fluorouracil; Gen | 2018 |
Managing the economic impact of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost Control; Cost-Benefit Analysis; Deoxycytidine; | 2019 |
Predicting the Efficacy of 5-Fluorouracil-Based Adjuvant Chemotherapy in Gastric Cancer by Microsatellite Instability: A Meta-Analysis.
Topics: Chemotherapy, Adjuvant; Fluorouracil; Humans; Microsatellite Instability; Proportional Hazards Model | 2019 |
Diagnosis and management of DNA mismatch repair-deficient colorectal cancer.
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; C | 2015 |
[Molecular pathology of colorectal cancer].
Topics: Adenocarcinoma; Algorithms; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Colorectal | 2015 |
Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Instabil | 2015 |
Microsatellite instability testing and its role in the management of colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2015 |
Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, T | 2016 |
Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients.
Topics: Animals; Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; DNA Mismatch Repair; Fluorour | 2017 |
Synchronous quintuple primary gastrointestinal tract malignancies: Case report.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cancer | 2017 |
Microsatellite instability: a predictive marker in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as | 2009 |
Genetic prognostic and predictive markers in colorectal cancer.
Topics: beta Catenin; Biomarkers, Tumor; Camptothecin; Capecitabine; Chromosomes, Human, Pair 18; Colorectal | 2009 |
[Pathological diagnosis for individualized therapy of colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
[Adjuvant therapy in colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical | 2010 |
Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; | 2010 |
[Difference of colon cancer and rectal cancer-from the view of an oncological physician].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Chromosomal In | 2010 |
Adjuvant colon cancer chemotherapy: where we are and where we'll go.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic N | 2010 |
Role of microsatellite instability in the management of colorectal cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Colore | 2013 |
[Lynch syndrome and microsatellite instability: a review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colorectal Neoplasms, Hereditary Nonpolyp | 2012 |
Exploring alternative individualized treatment strategies in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biological Therapy; Chemotherapy, Adjuvant; Colorecta | 2007 |
The role of molecular markers in predicting response to therapy in patients with colorectal cancer.
Topics: Algorithms; Antibody-Dependent Cell Cytotoxicity; Biomarkers, Tumor; Chromosomes, Human, Pair 18; Cl | 2008 |
21 trials available for fluorouracil and Microsatellite Instability
| Article | Year |
|---|---|
Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2022 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological | 2020 |
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological | 2020 |
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological | 2020 |
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance).
Topics: Aged; Cetuximab; Colonic Neoplasms; Disease-Free Survival; Fatty Acids, Omega-3; Female; Fish Oils; | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2013 |
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neopla | 2015 |
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarke | 2014 |
Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Female; Fluorourac | 2015 |
Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Fem | 2015 |
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetu | 2017 |
Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; DNA, Neoplasm; Drug The | 2008 |
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 8 | 2009 |
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2009 |
Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuv | 2009 |
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2009 |
Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 2010 |
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarke | 2012 |
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemot | 2012 |
Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxyc | 2007 |
88 other studies available for fluorouracil and Microsatellite Instability
| Article | Year |
|---|---|
Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition.
Topics: Apoptosis; Casein Kinase Ialpha; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; | 2021 |
Results of the observational prospective RealFLOT study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2021 |
The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Colonic Neoplasms; Colorectal Neoplasms; DNA; Epige | 2023 |
Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice.
Topics: Animals; Carcinogenesis; Fluorouracil; HSP110 Heat-Shock Proteins; Mice; Microsatellite Instability; | 2022 |
Gastric cancer with microsatellite instability displays increased thymidylate synthase expression.
Topics: B7-H1 Antigen; Fluorouracil; Humans; Microsatellite Instability; Microsatellite Repeats; Prognosis; | 2022 |
Dihydropyrimidine Dehydrogenase (DPD) as a Bridge between the Immune Microenvironment of Colon Cancers and 5-FU Resistance.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colonic Neoplasms; Dihydrouracil Dehydrogenase ( | 2023 |
PAIP 2020: Microsatellite instability prediction in colorectal cancer.
Topics: Artificial Intelligence; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Instability; Pro | 2023 |
EMAST status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for Stage II/III colorectal cancer.
Topics: Aged; Chemotherapy, Adjuvant; Colon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorourac | 2020 |
Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neopl | 2019 |
Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fem | 2020 |
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 2020 |
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Prot | 2020 |
Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2020 |
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Bi | 2021 |
The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer.
Topics: Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Microsatell | 2022 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2021 |
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and witho
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Biomarkers, Tumor; Clini | 2021 |
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Pro | 2021 |
Determination of therapeutic agents efficiencies of microsatellite instability high colon cancer cells in post-metastatic liver biochip modeling.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Screening Assays, Antitumor; | 2021 |
Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
DNA methylation-mediated repression of miR-181a/135a/302c expression promotes the microsatellite-unstable colorectal cancer development and 5-FU resistance via targeting PLAG1.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; DNA-Binding Proteins | 2018 |
Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2018 |
Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; CpG Islands; | 2018 |
Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2019 |
The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuv | 2018 |
Comment on "Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer": Are we There Yet?
Topics: Apoptosis; Biomarkers; Chemotherapy, Adjuvant; Fluorouracil; Humans; Microsatellite Instability; Pro | 2019 |
p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2019 |
Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2019 |
Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bile Duc | 2019 |
Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, | 2019 |
ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2013 |
Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2013 |
Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2013 |
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil.
Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Case-Control Stu | 2013 |
Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarke | 2014 |
The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses.
Topics: Adult; Aged; Drug Therapy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Microsatellite | 2015 |
Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Base Sequence; Cell Line, Tumor; Cell Survival; Colore | 2015 |
Truncating mutation in the autophagy gene UVRAG confers oncogenic properties and chemosensitivity in colorectal cancers.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Autophagy; Carcinogenesis; Cell Line, Tumor; | 2015 |
[Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases].
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bi | 2015 |
Autophagy is upregulated during colorectal carcinogenesis, and in DNA microsatellite stable carcinomas.
Topics: Apoptosis; Autophagy; Bevacizumab; Carcinogenesis; Chloroquine; Colorectal Neoplasms; Fluorouracil; | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C | 2015 |
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cis | 2017 |
The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2016 |
Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; DNA Methylation; Fem | 2016 |
Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetux | 2016 |
Microsatellite instability & survival in patients with stage II/III colorectal carcinoma.
Topics: Adult; Aged; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; H | 2016 |
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Topics: Aged; Biomarkers, Tumor; Colonic Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female | 2017 |
Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2017 |
BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; F | 2017 |
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; DNA | 2017 |
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplas | 2009 |
A simple colostomy implantation model for evaluating colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Colostomy; Disease Mo | 2009 |
Advances in defective mismatch repair colon cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Combined Chemotherap | 2008 |
Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Mismatch Repa | 2009 |
Colon cancer in a 16-year-old girl: signet-ring cell carcinoma without microsatellite instability--an unusual suspect.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Colonic Neo | 2009 |
Chemosensitivity and survival in gastric cancer patients with microsatellite instability.
Topics: Aged; Antimetabolites, Antineoplastic; Disease Progression; Female; Fluorouracil; Humans; Lymphatic | 2009 |
Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma.
Topics: Aged; Aged, 80 and over; Allelic Imbalance; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2009 |
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2010 |
An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.
Topics: Adenocarcinoma; Adenoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2010 |
Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuv | 2011 |
Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch?
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Resistance, Neop | 2010 |
[Microsatellite instability. A new predictive marker (?)].
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemothera | 2010 |
Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.
Topics: AC133 Antigen; Adenomatous Polyposis Coli; Aged; Aged, 80 and over; Animals; Antigens, CD; Antineopl | 2011 |
Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biomarkers; Chromosomes, Human, Pair 18; Color | 2011 |
Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Colorectal Neoplasms, | 2011 |
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Va | 2011 |
Overexpression of neurone glial-related cell adhesion molecule is an independent predictor of poor prognosis in advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Adhesion Molecules; Colorectal Neoplasms; Female; F | 2011 |
Gene expression variations in microsatellite stable and unstable colon cancer cells.
Topics: Colonic Neoplasms; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression | 2012 |
Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Fluorouracil; | 2012 |
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; DNA Primers; Fluor | 2011 |
The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Colonic Neoplasms; Female; Fluorouracil; Humans; | 2012 |
Colon cancer with microsatellite instability in a 13-year-old Hispanic male.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; DNA-Binding Proteins; | 2012 |
FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antimetabolites, Antineoplastic; Basic-Leucine Zipper Tr | 2012 |
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.
Topics: Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptot | 2012 |
Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2013 |
5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer.
Topics: Animals; Cell Count; Cell Survival; Colorectal Neoplasms; Disease Models, Animal; Flow Cytometry; Fl | 2006 |
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Disease-Free Survi | 2007 |
Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; | 2006 |
[Influence of neoadjuvant chemotherapy on microsatellite instability in gastric carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; DNA, Neoplasm; Fluorouracil; Humans; Leucovorin; Mic | 2006 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.
Topics: Aged; Apoptosis; bcl-2-Associated X Protein; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluo | 2007 |
Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Microsatellite Instabilit | 2007 |
Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features.
Topics: Adult; Aged; Cisplatin; DNA Methylation; Female; Fluorouracil; Humans; Loss of Heterozygosity; Male; | 2007 |
Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2008 |
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |